Drug Profile
Research programme: Parkinson's disease gene therapy - Takeda
Alternative Names: TH/GCH1 Gene PodLatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Shire
- Developer Takeda
- Class Gene therapies
- Mechanism of Action GTP cyclohydrolase modulators; Tyrosine hydroxylase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Parkinson's disease in USA (Parenteral) (Takeda pipeline, August 2023)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)
- 08 Jan 2019 Shire has been acquired and merged into Takeda